Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider Sells 27,594 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) insider Ross Moat sold 27,594 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total transaction of $800,777.88. Following the transaction, the insider now owns 9,415 shares of the company’s stock, valued at approximately $273,223.30. This represents a 74.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ross Moat also recently made the following trade(s):

• On Monday, May 5th, Ross Moat sold 6,272 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $28.00, for a total transaction of $175,616.00.
• On Tuesday, April 29th, Ross Moat sold 64,035 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $25.21, for a total transaction of $1,614,322.35.
• On Thursday, May 1st, Ross Moat sold 23,234 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $28.02, for a total transaction of $651,016.68.
• On Monday, April 21st, Ross Moat sold 18,259 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $20.29, for a total transaction of $370,475.11.

Kiniksa Pharmaceuticals Stock Up 2.4%

Shares of KNSA stock opened at $30.23 on Friday. The firm has a 50 day moving average price of $24.27 and a two-hundred day moving average price of $21.91. The company has a market capitalization of $2.21 billion, a PE ratio of -215.91 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $17.38 and a 12-month high of $30.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business’s revenue for the quarter was up 72.5% compared to the same quarter last year. During the same period last year, the business posted ($0.25) earnings per share. As a group, research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its position in Kiniksa Pharmaceuticals by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after acquiring an additional 568 shares during the last quarter. US Bancorp DE bought a new position in shares of Kiniksa Pharmaceuticals during the first quarter worth approximately $33,000. Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals during the first quarter worth approximately $41,000. Wealthquest Corp bought a new position in shares of Kiniksa Pharmaceuticals during the first quarter worth approximately $42,000. Finally, Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter worth approximately $61,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price for the company. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.